MedTrace Logo

Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea

NCT03059537 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2017-12-12

No results posted yet for this study

Summary

This study aims to validate a possible diagnostic test for bile acid diarrhoea prospectively compared to the SeHCAT scintigraphy. Fasting participants are given a standard meal and 1,250 mg chenodeoxycholic acid. The investigators measure fasting FGF19, bile acids species including 7-alpha-CHO and serial blood samples after the stimulation.

Conditions

  • Bile Acid Malabsorption

Interventions

DRUG

Oral chenodeoxycholic acid stimulation

oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor

Sponsors & Collaborators

  • Lars Kristian Munck

    lead OTHER

Principal Investigators

  • Christian Borup, MD · Zealand University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2017-11-27
Completion
2017-11-27

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03059537 on ClinicalTrials.gov